These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33993740)

  • 1. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.
    Dasari A; Sobrero A; Yao J; Yoshino T; Schelman W; Yang Z; Chien C; Kania M; Tabernero J; Eng C
    Future Oncol; 2021 Aug; 17(24):3151-3162. PubMed ID: 33993740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
    Xu RH; Li J; Bai Y; Xu J; Liu T; Shen L; Wang L; Pan H; Cao J; Zhang D; Fan S; Hua Y; Su W
    J Hematol Oncol; 2017 Jan; 10(1):22. PubMed ID: 28103904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial.
    Xu R; Qin S; Guo W; Bai Y; Deng Y; Yang L; Chen Z; Zhong H; Pan H; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Xu J; Chen D; Li W; Sun S; Yu Z; Cao P; Li J; Chen H; Wang J; Wang S; Wang H; Wang N; Zhang B; Han R; Su W; Guo X; Li J
    Future Oncol; 2021 Apr; 17(11):1339-1350. PubMed ID: 33325251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
    Dasari A; Lonardi S; Garcia-Carbonero R; Elez E; Yoshino T; Sobrero A; Yao J; García-Alfonso P; Kocsis J; Cubillo Gracian A; Sartore-Bianchi A; Satoh T; Randrian V; Tomasek J; Chong G; Paulson AS; Masuishi T; Jones J; Csőszi T; Cremolini C; Ghiringhelli F; Shergill A; Hochster HS; Krauss J; Bassam A; Ducreux M; Elme A; Faugeras L; Kasper S; Van Cutsem E; Arnold D; Nanda S; Yang Z; Schelman WR; Kania M; Tabernero J; Eng C;
    Lancet; 2023 Jul; 402(10395):41-53. PubMed ID: 37331369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
    Li J; Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Fan S; Hua Y; Su W
    JAMA; 2018 Jun; 319(24):2486-2496. PubMed ID: 29946728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.
    Fusco MJ; Casak SJ; Mushti SL; Cheng J; Christmas BJ; Thompson MD; Fu W; Wang H; Yoon M; Yang Y; Moore JN; Bi Y; Nan Y; Long CE; Auth D; Rahman NA; Tang S; Pazdur R; Fashoyin-Aje LA; Kluetz PG; Lemery SJ
    Clin Cancer Res; 2024 Aug; 30(15):3100-3104. PubMed ID: 38809262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial.
    Qin S; Li J; Bai Y; Deng Y; Yang L; Xu RH; Zhong H; Chen Z; Pan H; Guo W; Shu Y; Xu J; Peng C; Chen Y; Li H; Wang N; Guo X; Peng M; Fan S; Shen L
    Future Oncol; 2021 May; 17(15):1923-1931. PubMed ID: 33563040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
    Zhang Q; Wang Q; Wang X; Li J; Shen L; Peng Z
    Int J Colorectal Dis; 2020 Feb; 35(2):295-306. PubMed ID: 31848739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
    Stucchi E; Bartolini M; Airoldi M; Fazio R; Daprà V; Mondello G; Prete MG; Puccini A; Santoro A
    Expert Opin Pharmacother; 2024 Mar; 25(4):371-382. PubMed ID: 38568032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial.
    Li J; Guo W; Bai Y; Deng Y; Yang L; Chen Z; Zhong H; Xu R; Pan H; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Xu J; Chen D; Li W; Sun S; Yu Z; Cao P; Shen L; Chen H; Wang S; Wang H; Fan S; Guo X; Wang N; Han R; Zhang B; Qin S
    Adv Ther; 2020 Nov; 37(11):4585-4598. PubMed ID: 32901330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer.
    Zhang Y; Zou JY; Wang Z; Wang Y
    Cancer Manag Res; 2019; 11():7787-7803. PubMed ID: 31496821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fruquintinib and its use in the treatment of metastatic colorectal cancer.
    Deng Y; Li X
    Future Oncol; 2019 Aug; 15(22):2571-2576. PubMed ID: 31407939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of fruquintinib in Chinese patients with refractory metastatic colorectal cancer.
    Huang Z; Zhou L; Zheng H; Zhan M
    Int J Clin Pharm; 2024 Aug; 46(4):872-880. PubMed ID: 38642249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China.
    Guan X; Li H; Xiong X; Peng C; Wang N; Ma X; Ma A
    J Med Econ; 2021; 24(1):339-344. PubMed ID: 33571036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US.
    Paly VF; Dasari A; Hubbard J; Bekaii-Saab T; Padukkavidana T; Hernandez L
    J Comp Eff Res; 2024 Aug; 13(8):e240084. PubMed ID: 38976346
    [No Abstract]   [Full Text] [Related]  

  • 16. The clinical application of fruquintinib on colorectal cancer.
    Chen Z; Jiang L
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):713-721. PubMed ID: 31177854
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
    Chen J; Wang J; Lin H; Peng Y
    Med Sci Monit; 2019 Dec; 25():9179-9191. PubMed ID: 31790382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.
    Lu S; Chen G; Sun Y; Sun S; Chang J; Yao Y; Chen Z; Ye F; Lu J; Shi J; He J; Liu X; Zhang Y; Liu Z; Fang J; Cheng Y; Hu C; Mao W; Hu Y; Gong Y; Shan L; Yang Z; Song Y; Li W; Bai C; Wang B; Ma R; Zheng Z; Liu M; Jie Z; Cao L; Liao W; Pan H; Huang D; Chen Y; Yang J; Qin S; Ma S; Liang L; Liu Z; Zhou J; Tao M; Huang Y; Qiu F; Huang Y; Guan S; Peng M; Su W
    Lung Cancer; 2020 Aug; 146():252-262. PubMed ID: 32592986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis.
    Jing Z; Rui Z; Binglan Z
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2313-2323. PubMed ID: 31278474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer.
    Lu S; Chang J; Liu X; Shi J; Lu Y; Li W; Yang JJ; Zhou J; Wang J; An T; Yang L; Liu Z; Zhou X; Chen M; Hua Y; Su W
    J Clin Oncol; 2018 Apr; 36(12):1207-1217. PubMed ID: 29528793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.